Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting

Paul H Johnson1, Roger P Walker, Steven W Jones

  • 1Department of Cancer Research, Berlex Biosciences, Richmond, California 94804-0099, USA. JohnsonPaulH@att.net

Insights

A new multiplex gene expression (MGE) assay rapidly screens thousands of chemicals for cancer drug discovery. This technology identifies potent steroids that inhibit cancer genes and assesses compound toxicity, accelerating therapeutic development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer is a complex polygenic disease requiring novel drug discovery strategies targeting multiple genes.
  • Existing methods struggle to efficiently screen for compounds affecting multiple cancer-related targets simultaneously.

Purpose of the Study:

  • To develop and validate a cell-based, high-throughput screening technology for identifying drug candidates against multiple cancer targets.
  • To assess the utility of this technology for compound optimization and toxicological profiling.

Main Methods:

  • Developed a Multiplex Gene Expression (MGE) analysis using multiplexed detection coupled to reverse transcription-PCR for quantitative mRNA measurement.
  • Screened 9000 chemicals against six overexpressed cancer genes in PC-3 prostate cancer cells.
  • Utilized a second MGE assay to measure five toxicological markers (Hsp70, Gadd153, Gadd45, O6-methylguanine-DNA methyltransferase, cyclophilin).

Main Results:

  • Identified a class of steroids (cardiac glycoside analogs) that inhibit Na(+)K(+)-ATPase, downregulating four prostate cancer target genes including transcription factors and survivin.
  • Determined IC50 values and performed structure-activity analysis on identified compounds.
  • Demonstrated selective induction of apoptosis in cancer cells by representative compounds.
  • The toxicological MGE assay detected DNA damage and cellular stress more sensitively than cell viability assays.

Conclusions:

  • MGE analysis is a powerful tool for rapid drug screening, compound optimization, and simultaneous assessment of toxicological endpoints in cancer research.
  • The identified steroids represent a promising class of compounds for prostate cancer therapy.
  • This technology facilitates a deeper understanding of gene function in disease contexts.

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
DNA Microarrays02:34

DNA Microarrays

Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...